Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study.
LGS
Lennox-Gastaut syndrome
developmental and epileptic encephalopathy
perampanel
real-world evidence
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
21
03
2023
received:
10
01
2023
accepted:
28
03
2023
medline:
5
6
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
This retrospective study assessed long-term effectiveness of add-on perampanel (PER) in patients with Lennox-Gastaut syndrome (LGS). Outcomes included time to PER failure and time to seizure relapse in responders. PER failure was defined as either discontinuation of PER or initiation of another treatment. Seizure relapse in responders was defined as occurrence of a seizure in seizure-free patients and increase of at least 50% in average monthly seizure frequency for those who were responders. Eighty-seven patients were included. Treatment failure occurred in 52 (59.8%) subjects at a median time of 12 months. Treatment failure was due to lack of efficacy in 27 (52.0%) patients, lack of tolerability in 14 (27.0%), and both reasons in 11 (21.0%). A slower titration was associated with a lower risk of PER failure compared to faster titration schedules, and the occurrence of adverse events increased the risk of treatment failure. Thirty-six patients (41.4%) were responders during a median follow-up of 11 months. Seizure relapse occurred in 13 of 36 (36.1%) patients after a median time of 21 months. The overall rate of seizure responders was 23 of 87 (26.4%) at the end of follow-up. This study provides real-world evidence on the effectiveness of PER as adjunctive treatment in LGS patients.
Substances chimiques
perampanel
H821664NPK
Anticonvulsants
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e98-e104Informations de copyright
© 2023 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398-442.
Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021;4(4):CD003277.
Riva A, Coppola A, Bonaventura CD, Elia M, Ferlazzo E, Gobbi G, et al. An Italian consensus on the management of Lennox-Gastaut syndrome. Seizure. 2022;101:134-40.
Trinka E, Lattanzi S, Carpenter K, Corradetti T, Nucera B, Rinaldi F, et al. Exploring the evidence for broad-Spectrum effectiveness of Perampanel: a systematic review of clinical data in generalised seizures. CNS Drugs. 2021;35:821-37.
European Medicines Agency (EMA). Fycompa® summary of product characteristics. Eisai Europe Ltd [cited 2022 Aug 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf
Fycompa® prescribing information, Eisai Inc. Available from: https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. (Accessed December 2021).
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, et al. BRIVAFIRST group membership. Adjunctive Brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on first Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35(12):1289-301.
Lattanzi S, Cagnetti C, Foschi N, Ciuffini R, Osanni E, Chiesa V, et al. Adjunctive Perampanel in older patients with epilepsy: a multicenter study of clinical practice. Drugs Aging. 2021;38(7):603-10.
Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481-9.
French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117-25.
Auvin S, Dozieres B, Ilea A, Delanoë C. Use of perampanel in children and adolescents with Lennox-Gastaut syndrome. Epilepsy Behav. 2017;74:59-63.
Crespel A, Tang NPL, Macorig G, Gelisse P, Genton P. Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome. Seizure. 2020;75:66-9.
Alonso-Singer P, Aguilar-Amat Prior MJ, Oliva-Navarro J, Massot-Tarrús A, Giráldez BG, Bermejo P, et al. Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice. Epilepsy Behav. 2022;134:108836.
Villanueva V, D'Souza W, Goji H, Kim DW, Liguori C, McMurray R, et al. PERMIT pooled analysis participants. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol. 2022;269(4):1957-77.
Clinicaltrail-gov. NCT02834793: study of perampanel as adjunctive treatment for inadequately controlled seizures associated with Lennox-Gastaut syndrome. https://clinicaltrials.gov/ct2/show/study/NCT02834793
Biró A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110-6.
De Liso P, Vigevano F, Specchio N, De Palma L, Bonanni P, Osanni E, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res. 2016;127:93-100.
Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav. 2016;61:41-5.
Rohracher A, Zimmermann G, Villanueva V, Garamendi I, Sander JW, Wehner T, et al. Perampanel in routine clinical use across Europe: pooled, multicenter, observational data. Epilepsia. 2018;59(11):2167.
Huber B, Schmid G. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Epilepsy Behav. 2017;66:74-9.
Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32(10):905-16.
Tabaee Damavandi P, Fabin N, Giossi R, Matricardi S, Del Giovane C, Striano P, et al. Efficacy and safety of fenfluramine in epilepsy: a systematic review and meta-analysis. Neurol Ther. 2023;12(2):669-686.